Clinical trials of stereotactic ablative radiotherapy for prostate cancer: Updates and future direction

Future Oncology

Volumn 11, Issue 5, 2015, Pages 819-831

  Musunuru, H Bindu ^a,b   Loblaw, Andrew ^a,b,c  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

image guided radiotherapy; prostate cancer; quality of life; stereotactic ablative radiotherapy

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; CYBERKNIFE; DIFFUSION WEIGHTED IMAGING; DISEASE FREE SURVIVAL; DOSIMETRY; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; GANTRY BASED STEREOTACTIC BODY RADIATION THERAPY; HEMATURIA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOLOGICAL PROCEDURES; RECTUM FISTULA; RECTUM HEMORRHAGE; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC DEVICE; SYSTEMATIC REVIEW (TOPIC); THERAPY EFFECT; URINARY TRACT OBSTRUCTION; UROGENITAL ULCER; ADVERSE EFFECTS; MALE; MORTALITY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIOSURGERY; ROBOTIC SURGICAL PROCEDURE; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DOSE FRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOSURGERY; ROBOTIC SURGICAL PROCEDURES; TREATMENT OUTCOME;

EID: 84924807152     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.14     Document Type: Article

References (46)

1. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 43(5), 1095-1101 (1999).
2. Rew DA, Wilson GD. Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur. J. Surg. Oncol. 26(4), 405-417 (2000).
3. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int. J. Radiat. Oncol. Biol. Phys. 82(1), e17-e24 (2012).
4. Brenner DJ. Fractionation and late rectal toxicity. Int. J. Radiat. Oncol. Biol. Phys. 60(4), 1013-1015 (2004).
5. Fenoglietto P, Laliberte B, Allaw A et al. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk. Radiother. Oncol. 88(1), 77-87 (2008).
6. Ohri N, Dicker AP, Showalter TN. Late toxicity rates following definitive radiotherapy for prostate cancer. Can. J. Urol. 19(4), 6373-6380 (2012).
7. Collins CD, Lloyd-Davies RW, Swan AV. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin. Oncol. (R. Coll. Radiol.) 3(3), 127-132 (1991).
8. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 877-882(2012).
9. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6years. Radiat. Oncol. 8(1), 118 (2013).
10. Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol. 13, 49 (2013).
11. McBride SM, Wong DS, Dombrowski JJ et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional Phase 1 feasibility trial. Cancer 118(15), 3681-3690 (2012).
12. Jabbari S, Weinberg VK, Kaprealian T et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int. J. Radiat. Oncol. Biol. Phys. 82(1), 228-234 (2012).
13. Oliai C, Lanciano R, Sprandio B et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J. Radiat. Oncol. 2(1), 63-70 (2013).
14. Chen LN, Suy S, Uhm S et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat. Oncol. 8, 58 (2013).
15. Friedland JL, Freeman DE, Masterson-Mcgary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol. Cancer Res. Treat. 8(5), 387-392 (2009).
16. Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDR Cyber Knife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int. J. Radiat. Oncol. Biol. Phys. 70(5), 1588-1597 (2008).
17. King CR, Freeman D, Kaplan I et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiat. Oncol. 109(2), 217-221 (2013).
18. Alongi F, Cozzi L, Arcangeli S et al. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a Phase II study. Radiat. Oncol. 8, 171 (2013).
19. Boike TP, Lotan Y, Cho LC et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J. Clin. Oncol. 29(15), 2020-2026 (2011).
20. Macias VA, Blanco ML, Perez-Romasanta LA. Initial experience with stereotactic body radiation therapy for localized prostate cancer using helical tomotherapy. Clin. Transl. Oncol. 16(4), 380-385 (2014).
21. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int. J. Radiat. Oncol. Biol. Phys. 67(4), 1099-1105 (2007).
22. Menkarios C, Vigneault E, Brochet N et al. Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a Phase I/II trial. Radiat. Oncol. 6, 112 (2011).
23. Loblaw A, Cheung P, D'Alimonte L et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiat. Oncol. 107(2), 153-158 (2013).
24. ASTRO Model Policy on Stereotactic Body Radiation Therapy (SBRT) (2013). www.astro.org
25. Zaorsky NG, Harrison AS, Trabulsi EJ et al. Evolution of advanced technologies in prostate cancer radiotherapy. Nat. Rev. Urol. 10(10), 565-579 (2013).
26. Quon HC, Tang Ci, Pang G, et al. Dose escalation of 5-fraction radiation therapy for prostate cancer: quality of life comparison of 2 prospective trials. Int. J. Radiat. Oncol. Biol. Phys. 84(3 Suppl.), S148-S149 (2012).
27. Kim DW, Cho LC, Straka C et al. Predictors of rectal tolerance observed in a dose-escalated Phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 89(3), 509-517 (2014).
28. Crook J, Ots A, Gaztanaga M et al. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion. Brachytherapy 13(5), 433-441 (2014).
29. Morton G, Loblaw A, Cheung P et al. Is single fraction 15Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother. Oncol. 100(3), 463-467 (2011).
30. Pucar D, Hricak H, Shukla-Dave A et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int. J. Radiat. Oncol. Biol. Phys. 69(1), 62-69 (2007).
31. Arrayeh E, Westphalen AC, Kurhanewicz J et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int. J. Radiat. Oncol. Biol. Phys. 82(5), e787-e793 (2012).
32. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 6(2), 112-117 (2005).
33. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int. J. Radiat. Oncol. Biol. Phys. 68(1), 291-300 (2007).
34. Johnson LM, Turkbey B, Figg WD, Choyke PL. Multiparametric MRI in prostate cancer management. Nat. Rev. Clin. Oncol. 11(6), 346-353 (2014).
35. Barentsz JO, Richenberg J, Clements R et al. ESUR prostate MR guidelines 2012. Eur. Radiol. 22(4), 746-757 (2012).
36. Dickinson L, Ahmed HU, Allen C et al. Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J. Magn. Reson. Imaging 37(1), 48-58 (2013).
37. Langer DL, Van Der Kwast TH, Evans AJ et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 249(3), 900-908 (2008).
38. Van Der Heide UA, Houweling AC, Groenendaal G, Beets-Tan RG, Lambin P. Functional MRI for radiotherapy dose painting. Magn. Reson. Imaging 30(9), 1216-1223 (2012).
39. Bauman G, Haider M, Van Der Heide UA, Menard C. Boosting imaging defined dominant prostatic tumors: a systematic review. Radiother. Oncol. 107(3), 274-281 (2013).
40. Seung SK, Larson DA, Galvin JM et al. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS). Am. J. Clin. Oncol. 36(3), 310-315 (2013)
41. Jain P, Baker A, Distefano G, Scott AJ, Webster GJ, Hatton MQ. Stereotactic ablative radiotherapy in the UK: current status and developments. Br. J. Radiol. 86(1029), 20130331 (2013).
42. Amin NP, Sher DJ, Konski AA. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013. Appl. Health Econ. Health Policy 12(4), 391-408 (2014)
43. Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. J. Oncol. Pract. 8(3 Suppl.), e31s-e37s (2012).
44. Parthan A, Pruttivarasin N, Davies D et al. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front. Oncol. 2, 81 (2012).
45. Sharieff W, Greenspoon JN, Dayes I, Chow T, Wright J, Lukka H. The technique, resources and costs of stereotactic body radiotherapy of prostate cancer: a comparison of dose regimens and delivery systems. Technol. Cancer Res. Treat. doi:10.7785/tcrt.2012.500431(2014) (Epub ahead of print).
46. Sethukavalan P, Cheung P, Tang CI et al. Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: the benefits of hypofractionated over conventionally fractionated radiotherapy. Can. J. Urol. 19(2), 6165-6169 (2012).